4basebio (4BB) Competitors

GBX 439.50 -15.50 (-3.41%)

As of 11:01 AM Eastern

4BB vs. HZD, VRP, BTG, ARIX, and SCLP

Should you be buying 4basebio stock or one of its competitors? The main competitors of 4basebio include Horizon Discovery Group plc (HZD.L) (HZD), Verona Pharma plc (VRP.L) (VRP), BTG (BTG), Arix Bioscience (ARIX), and Scancell (SCLP). These companies are all part of the "biotechnology" industry.

How does 4basebio compare to Horizon Discovery Group plc (HZD.L)?

4basebio (LON:4BB) and Horizon Discovery Group plc (HZD.L) (LON:HZD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

In the previous week, 4basebio had 2 more articles in the media than Horizon Discovery Group plc (HZD.L). MarketBeat recorded 2 mentions for 4basebio and 0 mentions for Horizon Discovery Group plc (HZD.L). 4basebio's average media sentiment score of 0.00 equaled Horizon Discovery Group plc (HZD.L)'saverage media sentiment score.

Company	Overall Sentiment
4basebio	Neutral
Horizon Discovery Group plc (HZD.L)	Neutral

Horizon Discovery Group plc (HZD.L) has higher revenue and earnings than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than Horizon Discovery Group plc (HZD.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4basebio	£1.78M	38.26	-£9.84M	-£99.00	N/A
Horizon Discovery Group plc (HZD.L)	£54.63M	0.00	N/A	-£5.50	N/A

4basebio currently has a consensus target price of GBX 1,600, suggesting a potential upside of 264.05%. Given 4basebio's stronger consensus rating and higher probable upside, equities analysts clearly believe 4basebio is more favorable than Horizon Discovery Group plc (HZD.L).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4basebio	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Horizon Discovery Group plc (HZD.L)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

0.9% of 4basebio shares are owned by institutional investors. 12.1% of 4basebio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Horizon Discovery Group plc (HZD.L)'s return on equity of 0.00% beat 4basebio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4basebio	N/A	-231.29%	-54.30%
Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A

Summary

4basebio beats Horizon Discovery Group plc (HZD.L) on 7 of the 11 factors compared between the two stocks.

How does 4basebio compare to Verona Pharma plc (VRP.L)?

Verona Pharma plc (VRP.L) (LON:VRP) and 4basebio (LON:4BB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

4basebio has a consensus target price of GBX 1,600, suggesting a potential upside of 264.05%. Given 4basebio's stronger consensus rating and higher probable upside, analysts clearly believe 4basebio is more favorable than Verona Pharma plc (VRP.L).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verona Pharma plc (VRP.L)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
4basebio	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, 4basebio had 2 more articles in the media than Verona Pharma plc (VRP.L). MarketBeat recorded 2 mentions for 4basebio and 0 mentions for Verona Pharma plc (VRP.L). Verona Pharma plc (VRP.L)'s average media sentiment score of 0.00 equaled 4basebio'saverage media sentiment score.

Company	Overall Sentiment
Verona Pharma plc (VRP.L)	Neutral
4basebio	Neutral

Verona Pharma plc (VRP.L)'s return on equity of 0.00% beat 4basebio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verona Pharma plc (VRP.L)	N/A	N/A	N/A
4basebio	N/A	-231.29%	-54.30%

0.9% of 4basebio shares are held by institutional investors. 12.1% of 4basebio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Verona Pharma plc (VRP.L) has higher earnings, but lower revenue than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than Verona Pharma plc (VRP.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verona Pharma plc (VRP.L)	N/A	N/A	N/A	-£32.70	N/A
4basebio	£1.78M	38.26	-£9.84M	-£99.00	N/A

Summary

4basebio beats Verona Pharma plc (VRP.L) on 7 of the 11 factors compared between the two stocks.

How does 4basebio compare to BTG?

BTG (LON:BTG) and 4basebio (LON:4BB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

BTG currently has a consensus target price of GBX 160, indicating a potential upside of 35.59%. 4basebio has a consensus target price of GBX 1,600, indicating a potential upside of 264.05%. Given 4basebio's higher possible upside, analysts clearly believe 4basebio is more favorable than BTG.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BTG	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
4basebio	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, BTG had 1 more articles in the media than 4basebio. MarketBeat recorded 3 mentions for BTG and 2 mentions for 4basebio. BTG's average media sentiment score of 0.19 beat 4basebio's score of 0.00 indicating that BTG is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BTG	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
4basebio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BTG's return on equity of 0.00% beat 4basebio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BTG	N/A	N/A	N/A
4basebio	N/A	-231.29%	-54.30%

19.3% of BTG shares are owned by institutional investors. Comparatively, 0.9% of 4basebio shares are owned by institutional investors. 19.8% of BTG shares are owned by insiders. Comparatively, 12.1% of 4basebio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

BTG has higher revenue and earnings than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than BTG, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BTG	£159.40M	1.19	N/A	£6.00	19.67
4basebio	£1.78M	38.26	-£9.84M	-£99.00	N/A

Summary

BTG beats 4basebio on 9 of the 11 factors compared between the two stocks.

How does 4basebio compare to Arix Bioscience?

Arix Bioscience (LON:ARIX) and 4basebio (LON:4BB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

4basebio has a consensus target price of GBX 1,600, indicating a potential upside of 264.05%. Given 4basebio's stronger consensus rating and higher possible upside, analysts clearly believe 4basebio is more favorable than Arix Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arix Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
4basebio	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, 4basebio had 2 more articles in the media than Arix Bioscience. MarketBeat recorded 2 mentions for 4basebio and 0 mentions for Arix Bioscience. Arix Bioscience's average media sentiment score of 0.00 equaled 4basebio'saverage media sentiment score.

Company	Overall Sentiment
Arix Bioscience	Neutral
4basebio	Neutral

Arix Bioscience has a net margin of 105.64% compared to 4basebio's net margin of 0.00%. Arix Bioscience's return on equity of 6.41% beat 4basebio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arix Bioscience	105.64%	6.41%	2.18%
4basebio	N/A	-231.29%	-54.30%

41.3% of Arix Bioscience shares are owned by institutional investors. Comparatively, 0.9% of 4basebio shares are owned by institutional investors. 20.7% of Arix Bioscience shares are owned by insiders. Comparatively, 12.1% of 4basebio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Arix Bioscience has higher revenue and earnings than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arix Bioscience	£14.16M	0.00	£14.96M	£0.11	N/A
4basebio	£1.78M	38.26	-£9.84M	-£99.00	N/A

Arix Bioscience has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market. Comparatively, 4basebio has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market.

Summary

Arix Bioscience beats 4basebio on 9 of the 14 factors compared between the two stocks.

How does 4basebio compare to Scancell?

Scancell (LON:SCLP) and 4basebio (LON:4BB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

In the previous week, Scancell and Scancell both had 2 articles in the media. Scancell's average media sentiment score of 0.10 beat 4basebio's score of 0.00 indicating that Scancell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scancell	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
4basebio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

4basebio has a consensus target price of GBX 1,600, indicating a potential upside of 264.05%. Given 4basebio's stronger consensus rating and higher probable upside, analysts clearly believe 4basebio is more favorable than Scancell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scancell	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
4basebio	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Scancell has higher revenue and earnings than 4basebio. Scancell is trading at a lower price-to-earnings ratio than 4basebio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scancell	£4.71M	40.75	-£6.75M	-£0.55	N/A
4basebio	£1.78M	38.26	-£9.84M	-£99.00	N/A

4basebio has a net margin of 0.00% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat 4basebio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scancell	-116.98%	90.29%	-45.28%
4basebio	N/A	-231.29%	-54.30%

Scancell has a beta of 0.573, indicating that its stock price is 43% less volatile than the broader market. Comparatively, 4basebio has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market.

1.5% of Scancell shares are owned by institutional investors. Comparatively, 0.9% of 4basebio shares are owned by institutional investors. 15.5% of Scancell shares are owned by insiders. Comparatively, 12.1% of 4basebio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Scancell beats 4basebio on 9 of the 15 factors compared between the two stocks.

Get 4basebio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding 4BB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

4BB vs. The Competition

Export

Metric	4basebio	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£68.06M	£457.64M	£6.28B	£2.76B
Dividend Yield	N/A	3.86%	2.78%	6.14%
P/E Ratio	-4.44	4.14	20.49	365.60
Price / Sales	38.26	7,693.05	544.52	88,654.25
Price / Cash	16.08	13.13	27.81	27.89
Price / Book	-10.72	79.78	9.58	7.52
Net Income	-£9.84M	-£96.07M	£3.55B	£5.89B
7 Day Performance	-8.44%	0.32%	-0.82%	7.44%
1 Month Performance	-17.03%	3.15%	5.46%	2.90%
1 Year Performance	-60.05%	73.68%	37.70%	89.21%

4basebio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
4BB 4basebio	1.8871 of 5 stars	GBX 439.50 -3.4%	GBX 1,600 +264.1%	-59.1%	£68.06M	£1.78M	N/A	101	News Coverage Gap Up High Trading Volume
HZD Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A	N/A	£302.98M	£54.63M	N/A	416
VRP Verona Pharma plc (VRP.L)	N/A	N/A	N/A	N/A	£228M	N/A	N/A	22	Gap Up
BTG BTG	3.8778 of 5 stars	GBX 118.50 -0.8%	GBX 160 +35.0%	N/A	£190.85M	£159.40M	19.75	4,690	Gap Down
ARIX Arix Bioscience	N/A	N/A	N/A	N/A	£183.73M	£14.16M	1,290.91	9

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:4BB) was last updated on 5/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

4basebio (4BB) Competitors

4BB vs. HZD, VRP, BTG, ARIX, and SCLP

How does 4basebio compare to Horizon Discovery Group plc (HZD.L)?

Summary

How does 4basebio compare to Verona Pharma plc (VRP.L)?

Summary

How does 4basebio compare to BTG?

Summary

How does 4basebio compare to Arix Bioscience?

Summary

How does 4basebio compare to Scancell?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

4BB vs. The Competition

4basebio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

4basebio (4BB) Competitors

4BB vs. HZD, VRP, BTG, ARIX, and SCLP

How does 4basebio compare to Horizon Discovery Group plc (HZD.L)?

Does the media favor 4BB or HZD?

Which has higher earnings and valuation, 4BB or HZD?

Do analysts recommend 4BB or HZD?

Do insiders and institutionals have more ownership in 4BB or HZD?

Is 4BB or HZD more profitable?

Summary

How does 4basebio compare to Verona Pharma plc (VRP.L)?

Do analysts recommend VRP or 4BB?

Does the media prefer VRP or 4BB?

Is VRP or 4BB more profitable?

Do insiders & institutionals have more ownership in VRP or 4BB?

Which has preferable valuation & earnings, VRP or 4BB?

Summary

How does 4basebio compare to BTG?

Do analysts rate BTG or 4BB?

Does the media favor BTG or 4BB?

Is BTG or 4BB more profitable?

Do insiders and institutionals have more ownership in BTG or 4BB?

Which has higher valuation and earnings, BTG or 4BB?

Summary

How does 4basebio compare to Arix Bioscience?

Do analysts rate ARIX or 4BB?

Does the media favor ARIX or 4BB?

Is ARIX or 4BB more profitable?

Do insiders and institutionals have more ownership in ARIX or 4BB?

Which has higher valuation and earnings, ARIX or 4BB?

Which has more risk & volatility, ARIX or 4BB?

Summary

How does 4basebio compare to Scancell?

Does the media refer more to SCLP or 4BB?

Do analysts recommend SCLP or 4BB?

Which has stronger valuation & earnings, SCLP or 4BB?

Is SCLP or 4BB more profitable?

Which has more volatility and risk, SCLP or 4BB?

Do institutionals and insiders have more ownership in SCLP or 4BB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

4BB vs. The Competition

4basebio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools